Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications
Charles M. Rudin , Erika Avila-Tang , Curtis C. Harris , James G. Herman
Clinical Cancer Research 15 ( 18) 5646 -5661
192
2009
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.
Nicolas Girard , Ronglai Shen , Tianhua Guo , Maureen F. Zakowski
Clinical Cancer Research 15 ( 22) 6790 -6799
185
2009
Genomic and Mutational Profiling to Assess Clonal Relationships Between Multiple Non–Small Cell Lung Cancers
Nicolas Girard , Irina Ostrovnaya , Christopher Lau , Bernard Park
Clinical Cancer Research 15 ( 16) 5184 -5190
103
2009
Integration of Molecular Profiling into the Lung Cancer Clinic
William Pao , Mark G. Kris , A. John Iafrate , Marc Ladanyi
Clinical Cancer Research 15 ( 17) 5317 -5322
72
2009
Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report
Nicolas Girard , Emil Lou , Christopher G. Azzoli , Rekha Reddy
Clinical Cancer Research 16 ( 2) 755 -763
100
2010
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Gregory J. Riely , Mark G. Kris , Binsheng Zhao , Tim Akhurst
Clinical Cancer Research 13 ( 17) 5150 -5155
340
2007
Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method.
William Pao , Marc Ladanyi
Clinical Cancer Research 13 ( 17) 4954 -4955
193
2007
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
James Bean , Gregory J. Riely , Marissa Balak , Jenifer L. Marks
Clinical Cancer Research 14 ( 22) 7519 -7525
217
2008
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
Gregory J. Riely , Mark G. Kris , Daniel Rosenbaum , Jenifer Marks
Clinical Cancer Research 14 ( 18) 5731 -5734
657
2008
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
Daniel B. Costa , Kim-Son H. Nguyen , Byoung C. Cho , Lecia V. Sequist
Clinical Cancer Research 14 ( 21) 7060 -7067
136
2008
Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib
Vincent A. Miller , Gregory J. Riely , Maureen F. Zakowski , Allan R. Li
Journal of Clinical Oncology 26 ( 9) 1472 -1478
265
2008
Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy
Chih-Hsin Yang , Chong-Jen Yu , Jin-Yuan Shih , Yeun-Chung Chang
Journal of Clinical Oncology 26 ( 16) 2745 -2753
214
2008
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
Catherine A. Eberlein , Daniel Stetson , Aleksandra A. Markovets , Katherine J. Al-Kadhimi
Cancer Research 75 ( 12) 2489 -2500
285
2015
EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.
Katherine R. Amato , Shan Wang , Li Tan , Andrew K. Hastings
Cancer Research 76 ( 2) 305 -318
54
2016
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.
Eiki Ichihara , David Westover , Catherine B. Meador , Yingjun Yan
Cancer Research 77 ( 11) 2990 -3000
99
2017
Somatic mutations of the Parkinson's disease–associated gene PARK2 in glioblastoma and other human malignancies
Selvaraju Veeriah , Barry S Taylor , Shasha Meng , Fang Fang
Nature Genetics 42 ( 1) 77 -82
381
2010
A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC).
Bruce E Johnson , Mark G Kris , Lynne D Berry , David J Kwiatkowski
Journal of Clinical Oncology 31 8019 -8019
46
2013
Clinical and pathologic characteristics of patients with PI3K-mutant breast cancers.
M. Cooper Lloyd , Melinda Sanders , Maria Gabriela Kuba , Jaime Farley
Journal of Clinical Oncology 31 8 -8
2
2013
Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases
Yihua Sun , Yan Ren , Zhaoyuan Fang , Chenguang Li
Journal of Clinical Oncology 28 ( 30) 4616 -4620
364
2010
How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers
Katerina Politi , William Pao
Journal of Clinical Oncology 29 ( 16) 2273 -2281
95
2011